翌韬 向

Mr. 翌韬 向

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
LLLingjie Li
Lingjie Li
翌向翌韬 向
翌韬 向
煜蔡煜杰 蔡
煜杰 蔡
FLFangzhen Luo
Fangzhen Luo
MicroRNAs (miRNAs) are essential post-transcriptional regulators of gene expression and have emerged as key modulators of host–pathogen interactions during bacterial infection. In this narrative review, we synthesize recent experimental and mechanistic evidence on how infection-responsive miRNAs shape innate and adaptive immunity, focusing on four representative pathogens: Salmonella, Listeria monocytogenes, Mycobacterium tuberculosis, and Helicobacter pylori. We highlight major miRNA-regulated signaling modules, including TLR/NF-κB, JAK–STAT, autophagy, immunometabolic reprogramming, and extracellular vesicle mediated intercellular communication, and summarize experimentally validated miRNA–target interactions that calibrate immune activation thresholds and inflammatory outcomes. Accumulating evidence indicates that miRNAs not only fine-tune host defense programs by controlling immune-related gene expression and immune cell activation, but can also be exploited by bacterial pathogens to suppress antimicrobial signaling and promote intracellular survival or persistent colonization. Collectively, these findings position miRNAs as a critical regulatory layer linking immune signaling networks to infection outcomes and underscore their translational potential as biomarkers and host directed therapeutic targets, while remaining grounded in current experimental evidence.
1

27 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
翌向翌韬 向
翌韬 向
WCWeisheng Chen
Weisheng Chen
YXYina Xuan
Yina Xuan
GCGuangying Chen
Guangying Chen
LYLi Yu
Li Yu
FLFangzhen Luo
Fangzhen Luo
Although Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa are all classified as carbapenem-resistant, they differ in how they control antibiotic access to its targets. This narrative review concerns resistant clinical isolates. It compares β-lactamases, drug uptake and efflux, and penicillin-binding proteins (PBPs), including their implications for β-lactam treatment. We use enzyme–transport–target architecture to describe functional relationships among these components in a specified organism and drug context. Evidence from the examined systems links protein homeostasis to enzyme stability, transport alterations to drug-specific responses, and treatment to changes in resistance determinants and bacterial population composition. For example, a PBP3 substitution increased the sulbactam–durlobactam MIC eightfold in an Acinetobacter baylyi model, whereas another substitution altered purified-protein reactivity without increasing the MIC. Clinical treatment evidence is assessed separately from these mechanistic findings. The review distinguishes pathogen-focused trials, observational outcomes and in vitro activity, and relates treatment options to carbapenemase class, susceptibility and infection site. It helps explain why shared resistance determinants can produce different susceptibility profiles by linking enzyme activity, drug access and target engagement to the response to specific β-lactams.